The Impact of Metformin on Survival Outcomes in Patients with Comorbid Cancer and Type 2 Diabetes Mellitus
Abstract
Type 2 diabetes mellitus (T2DM) is a common condition that affects hundreds of millions of people worldwide. It occurs when the body does not use insulin properly, leading to high blood sugar. Insulin is a hormone made by the pancreas that helps move sugar from the blood into the body’s cells, where it can be used for energy. Many people with T2DM take metformin, a safe and affordable medication that lowers blood sugar and improving how the body responds to insulin. Because of these benefits, it is one of the most widely prescribed drugs for diabetes. In recent years, researchers have discovered that metformin may have health benefits beyond diabetes. It may help with obesity (excess weight that increases the risk of illness) and may help protect against heart disease. There is also interest in whether metformin might improve outcomes for people who have both cancer and diabetes. Many patients live with both conditions, which makes treatment decisions more complex. Some studies have suggested that patients taking metformin may live longer, but the results have not been consistent. Some of these studies may be misleading because of a problem called immortal time bias. In cancer clinical trials, patients are not randomly assigned to "metformin use" or "non-use" at the start of the trial. Instead, metformin is prescribed by physicians during the trial follow-up visits when medically needed to treat diabetes. Because patients must remain alive long enough to reach the follow-up…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.